SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1 Completed 39 enrolled NCIC Clinical Trials Group S*BIO · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating patients with locally advanced or metastatic solid tumors.

Timeline

Start: 2007-09-14
Primary completion: 2010-04-22
Completion: 2011-06-21

Publications

Results Razak AR, Hotte SJ, Siu LL, Chen EX, Hirte HW, Powers J, Walsh W, Stayner LA, Laughlin A, Novotny-Diermayr V, Zhu J, Eisenhauer EA. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer. 2011 Mar 1;104(5):756-62. doi: 10.1038/bjc.2011.13. Epub 2011 Feb 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pracinostat	Other / unclassified	60 mg	Oral
Subject	Pracinostat	Other / unclassified	90 mg	Oral

Indications

No indication recorded.